Anzeige
Mehr »
Login
Montag, 25.10.2021 Börsentäglich über 12.000 News von 675 internationalen Medien
Gamechanger-Meldung, Ausbruch und Indikatoren auf “Strong Buy”
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche

Aktuelle News von Endpoints News

  • 24 h
  • letzte 200 News
ZeitAktuelle Nachrichten
17:36As buzz on Califf FDA nom heats up, industry and agency insiders offer a strong nod for the 'perfect' choice
17:36Covid-19 roundup: Moderna says vaccine produces 'strong' response in 5- to 11-year-olds; Aspen Pharmacare plans to up vaccine production in South Africa - report
17:36Avenue Therapeutics lands an FDA adcomm for troubled flagship drug; FDA approves eye injection treatment for fluid buildup
16:36Feud between bluebird and a rival continues with a lawsuit and allegations of patent fraud
16:36A combo of AstraZeneca's Imfinzi and chemo wins where others have failed in pivotal biliary tract test
16:36Recent court decision pushes FDA to reject and reclassify drug-device combo, crushing shares
16:36Endo taps bent veggie in first Xiaflex brand campaign for Peyronie's disease curved erection condition
15:36Merck's experimental HIV drug islatravir hits with a PhIII combo win and FDA filing plans
15:36A transatlantic biotech flags a painful PhIII cancer flop, waving a white flag
14:36Another NASH player retreats from battered field after toxicology study flags potential delay
14:36Just as first Lucentis biosimilar wins approval, Roche snags an OK for an easier route of administration
13:36Sanofi, Regeneron gear up for new Dupixent filing after clearing second PhIII for eosinophilic esophagitis
13:36After passing on Acceleron, Bristol Myers Squibb eyes bolt-on acquisition of autoimmune specialist - report
12:36Novartis' second attempt to replicate a stunning cancer result falls flat
SaSo - that pig-to-human transplant; Potential diabetes cure reaches patient; Accused MIT scientist lashes back; and more
FrXilio Therapeutics goes public as biopharma IPOs rumble forward in Q4
FrA new Treg player emerges with $46M and backing from Takeda
FrOncopeptides stock craters as it pulls cancer drug Pepaxto from the market
FrOcular Therapeutix hammered by a PhII failure in dry eye disease - shares tank
FrNo, scientists are not any closer to pig-to-human transplants than they were last week
FrAgenus calls out FDA for playing favorites with Merck, pulls cervical cancer BLA at agency's request
FrFormer MIT scientist David Sabatini fires back at accuser, Whitehead Institute for 'false' harassment allegations
FrFollowing August meltdown, Zymergen hints at salvage plans - cutting jobs and renegotiating loans
FrCovid-19 roundup: White House pushes for IP waiver support to WTO; Rare nerve disorder listed as AstraZeneca side effect in UK
FrSanofi, Regeneron etch out another PhIII victory for Dupixent, easing severe itch and clearing lesions